Kyriakos Mitsotakis announced on Thursday at the Prix Galien Greece 2025 awards at the Music Hall.

“We will bring a very important initiative to the House next week. This is none other than automatic specialty recognition and consequently the specialization of doctors who have acquired it in the United States, provided that it is in place, it will correspond to positions in Greece, “he said,” Prime minister.

He pointed out that this is an important initiative and in this way opens a way for a repatriation of an animated potential, distinguished scientists, from the United States They want to return to our homeland and support the national health system.

“And we want scientists to be able to see their future in our country, looking for a quality of life that our country is undoubtedly offering, but next to their professional ambition and combining their own personal goals with the country’s collective prosperity,” he said.

Mr Mitsotakis said the prizes “Prix Galien Greece 2025” is a celebration that honors the Greek and international pharmaceutical industry and especially the pioneers in the development of innovative public health therapies.

“It is an area in which our country aspires to become a dynamic hub in our wider area. Remember that 45 of its 400 drug plants are hosted here Europewe produce almost 10% of its total preparations. And at national level, this means that the needs of Greek patients are covered by more than 60%, while at the same time serving the demand for markets in other Member States, “he noted.

He pointed out that European autonomy does not cease to be a crucial issue in this area.

“That is why, both Greek and multinational companies now have to step up their efforts with new investments, with more research centers. For its part, the state in turn gives its own “present”, fighting bureaucracy, reducing tax burdens, giving significant additional incentives for investment, such as the investment clawback which proved to be extremely successful. Our goal is to direct more resources to production, research, clinical trials. And all this has so far brought investment initiatives close to 1.5 billion euros. It is, that is, initiatives with a visible imprint on the scientific community and with a multiple impact on both the economy and society, “he continued.

The prime minister said that the government’s choice is to understand the operation of the NHS as a single national priority.

“In other words, as a common field of action not only public but also in the private sector, where prevention will meet treatment, the drug will justify its practical mission to the patient. And, secondly, the State to turn to our vibrant potential, both inside and outside the country, “he added.

He also said that it is no coincidence that in the pharmaceutical industry in our country, many minds are working today and have been repatriated, especially in recent years, “and this is exactly what we are seeking to happen to the national health system”.

He pointed out that in the last five years 10 new factories, 14 new research centers have been created, thereby shaping a new productive grid that will provide increasingly added value to the place.

“After all, the steps that are taking are many. Remember that one of the first seven European factories is being built today in Lavrio, focusing on the supercomputer “Daedalus”. It is a critical infrastructure that can support significant research associated with artificial intelligence in all areas, but mainly in the health sector, which has also been identified by the National Artificial Intelligence Strategy as one of the areas in which our country can really pioneer in the world. Which will grow around health, “he said, adding:” And I would say that it is an additional bridge of cooperation, precisely this public infrastructure, between private and public sectors, which will ultimately unlock our ability to provide better medicines, better services to citizens, but not to Greece,

The prime minister also said that the drug, of course, cannot be another product among other or just an economical profit opportunity, but there is much more. “You live it everyday and first and foremost, those who need it are the most. So we will continue to coordinate our actions, the Ministry, EOPYY, AEO, industry, patient associations that we have supported and which we believe very much, with a common pursuit of a three-year framework agreement that will ensure the self-evident: in every citizen, we can do the best of the right, either for the right, They are available to the exact treatments that come and which our fellow citizens need today, “he said.

And he said: “And I must tell you that the Ministry is already being considered the establishment of an innovation fund that will facilitate transitional compensation for new medicines so that they can enter the list faster. A move, of course, parallel to the improvements still required both in EOPYY pharmacies and home tradition, which begins soon. “

In addition, it recalled the 1.6 billion euros of “injections” given to the pharmaceutical industry all the time in various ways, as well as the intention of the government, which is already beginning to bring results so that we can reduce the cost of the clawback, “I would say” one “. Reforms that, be careful, will reduce waste coming from a bad past. And I don’t think I find it difficult to admit that the Greek market had its problems. “

Mr Mitsotakis said that we are now at a much better point and that we have in our hands tools that can control real -time spending such as electronic prescription, the Horizon drug evaluation system that has evolved and the electronic health file, which can provide anyone with each other,

“A wealth of data which, as I said, can then be analyzed by artificial intelligence tools by leading to new applications, new solutions and new effective public health policies,” he noted.

He also added to increase clinical trials that we already have results, as from 100 in 2019, we are at 564 and want to reach 1,000 in 2027.

“For the first time I was informed that we had Greece a Phase I study, Phase 1 at Papageorgiou Hospital in Thessaloniki, while seeking to create pockets in the National Health System that would implement similar innovative research within the National Health System,” he added.

Mr Mitsotakis said that the drug industry is a special dynamic industry, especially for our country, as we have significant comparative advantages that make us internationally competitive. “In particular, at a time when both in Europe and in our country we realize that it is a one -way bold changes in order to maintain and, above all, to improve our presence in world markets. However, if the uncertainty about international trade relations can generate a tendency for inactivity, it is a fact that every such rearrangement generates important opportunities. We must, therefore, see how we attract Europe, but especially in our homeland, talents, investments, emphasizing innovation pioneering in the field of living sciences, research, the development of new drugs, to eventually reach high level of medical services.

And concluding: “This is our vision in simple words. I believe it is both yours and this route is called upon to travel, at a time when demographic trends unfortunately raise new challenges for health systems. It is challenges that require us to use every idea of ​​the proper use of public resources, providing quality care, which concerns us all.

And I want to dwell here, ending, in the great importance that our government has attributed to prevention and public health actions, so as not to cure the disease but to make sure to prevent it. These are the actions that I believe have been universal recognition from the Greek state and we already have the first very important measurable results in a number of diseases, literally saving lives, because we have persuaded our fellow citizens to utilize this possibility that the Greek state gives them free of charge.

So warm congratulations to the organizers of today’s event. Warmest congratulations to Ms Apostolopoulou, who adorns the global research community and which we will have the pleasure of awarding, but also to all the recipients of the awards for their significant contribution. “